Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:
- an article about “[r]ival drugmakers Viatris and Merck . . . settl[ing] their yearslong dispute over patents on brand name diabetes treatments”;
- another article about a petition to the Supreme Court asking “the high court to review an appeals court’s decision that patents can only be issued to human inventors”; and
- a blog post about another Supreme Court petition “ask[ing] the Supreme Court to overturn the Federal Circuit’s ruling that Ingenio was estopped from challenging the validity of patent claims that were denied institution during inter partes review (IPR) validity proceedings at the Patent Trial and Appeal Board.”